title: Three-day standard dose cytarabine could induce an M4Eo patient into complete remission.
authors.affiliation: Division of Hematology, Showa University Fujigaoka Hospital, Yokohama, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Higuchi
authors.forename: F
authors.initials: F
authors.lastname: Saito
authors.forename: H
authors.initials: H
authors.lastname: Mori
authors.forename: M
authors.initials: M
authors.lastname: Omine
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use*; D006801:Humans; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000188:drug therapy*; D013274:Stomach Neoplasms / Q000473:pathology*
chemical_list: D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine